Marc A Bruce

age ~67

from Saint Cloud, FL

Get Report

Also known as:

Marc A Ruce

Phone and address:: 717 Tennessee Ave, Saint Cloud, FL 34769

Connected to:

Marc Bruce Phones & Addresses

717 Tennessee Ave, Saint Cloud, FL 34769
Yucca Valley, CA
Forest Falls, CA
Anza, CA
Escondido, CA
Desert Center, CA
San Marcos, CA
San Bernardino, CA
Oceanside, CA

Medicine Doctors

Marc B. Bruce

view source

Specialties:

Diagnostic Radiology

Work:

Providence Saint Mary Medical Center Radiology
401 W Poplar St, Walla Walla, WA 99362
(509)5225850 (phone), (509)5225887 (fax)

Education:

Medical School
University of Washington SOM
Graduated: 2002

Languages:

English

Description:

Dr. Bruce graduated from the University of Washington SOM in 2002. He works in Walla Walla, WA and specializes in Diagnostic Radiology. Dr. Bruce is affiliated with Providence St Mary Medical Center.

Us Patents

Trisubstituted Aryl And Heteroaryl Derivatives As Modulators Of Metabolism And The Prophylaxis And Treatment Of Disorders Related Thereto
view source
US Patent:

7470699, Dec 30, 2008
Filed:

Jul 9, 2004
Appl. No.:

10/888747
Inventors:

Robert M. Jones - San Diego CA, US
Graeme Semple - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Young-Jun Shin - San Diego CA, US
Albert S. Ren - San Diego CA, US
Imelda Calderon - San Diego CA, US
Beatriz Fioravanti - Tucson AZ, US
Jin Sun Karoline Choi - San Diego CA, US
Juerg Lehmann - San Diego CA, US
Marc A. Bruce - San Marcos CA, US
Assignee:

Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:

C07D 401/12
A61K 31/506
US Classification:

514269, 544319
Abstract:

The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism.

Trisubstituted Aryl And Heteroaryl Derivatives As Modulators Of Metabolism And The Prophylaxis And Treatment Of Disorders Related Thereto
view source
US Patent:

7838525, Nov 23, 2010
Filed:

Nov 21, 2006
Appl. No.:

11/602775
Inventors:

Robert M. Jones - San Diego CA, US
Graem Semple - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Young-Jun Shin - San Diego CA, US
Albert S. Ren - San Diego CA, US
Imelda Calderon - San Diego CA, US
Beatriz Fioravanti - Tuscon AZ, US
Jin Sun Karoline Choi - San Diego CA, US
Juerg Lehmann - San Diego CA, US
Marc A. Bruce - San Marcos CA, US
Assignee:

Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:

A61K 31/506
C07D 401/12
US Classification:

5142358, 51425218, 514269, 544122, 544295, 544296, 544319
Abstract:

The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism.

1,2,3-Trisubstituted Aryl And Heteroaryl Derivatives As Modulators Of Metabolism And The Prophylaxis And Treatment Of Disorders Related Thereto
view source
US Patent:

8546429, Oct 1, 2013
Filed:

Oct 13, 2010
Appl. No.:

12/903976
Inventors:

Robert M. Jones - San Diego CA, US
Graeme Semple - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Young-Jun Shin - San Diego CA, US
Albert S. Ren - San Diego CA, US
Imelda Calderon - San Diego CA, US
Beatriz Fioravanti - Tucson AZ, US
Jin Sun Karoline Choi - San Diego CA, US
Juerg Lehmann - San Diego CA, US
Marc Bruce - Escondido CA, US
Assignee:

Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:

C07D 211/46
C07D 401/14
A61K 31/4545
US Classification:

514318, 546193, 546194
Abstract:

The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism.

Gpr41 And Modulators Thereof For The Treatment Of Insulin-Related Disorders
view source
US Patent:

20080312277, Dec 18, 2008
Filed:

Nov 1, 2005
Appl. No.:

11/666910
Inventors:

James N. Leonard - San Diego CA, US
Zhi Liang Chu - San Diego CA, US
Marc A. Bruce - Escondido CA, US
P. Douglas Boatman - San Diego CA, US
International Classification:

A61K 31/47
G01N 33/566
C07D 215/38
A61P 3/10
A61K 31/4709
C07D 407/04
US Classification:

514314, 436501, 546169, 546167, 514311
Abstract:

The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is increased, wherein an increase in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is decreased, wherein a decrease in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound.